| Drug | Indication | Discovery | IND enabling | Phase 1 (Autoimmune) |
|---|---|---|---|---|
| Cizutamig (BCMAxCD3) |
Autoantibody driven autoimmune diseasesa | |||
| CND261 (CD20xCD3) |
Autoimmune diseasesb | |||
| CND319 (CD19xCD20xCD3) |
Autoimmune diseases | |||
| Not disclosed | Immunology indications | |||
| Not disclosed | Immunology indications | |||
| Discovery | IND enabling | Phase 1 (Autoimmune) |
| Cizutamig (BCMAxCD3) | ||
| Autoantibody driven autoimmune diseasesa | ||
| CND261 (CD20xCD3) | ||
| Autoimmune diseasesb | ||
| CND319 (CD19xCD20xCD3) | ||
| Autoimmune diseases | ||
| Not disclosed | ||
| Immunology indications | ||
| Not disclosed | ||
| Immunology indications | ||
aPhase 1 RRMM completed (40 patients)
bPhase 1 NHL completed (93 patients)
CIZUTAMIG (BCMAxCD3) Antibody
Cizutamig is a BCMAxCD3 bispecific antibody designed to target and eliminate later stage B-cells which are responsible for producing harmful autoantibodies. While Anti-FcRn therapies have shown promise in treating autoantibody-driven diseases, emerging clinical evidence suggests that targeting BCMA can lead to deeper and more effective responses compared to Anti-FcRn therapies. Having successfully completed a Phase 1 dose escalation study in oncology patients, cizutamig is now being developed by Candid for potential use in autoimmune diseases.
CND261 (CD20xCD3) Antibody
CND261 is a CD20xCD3 bispecific antibody designed to target a broad range of B-cell subtypes, from pro B-cells to plasmablasts/plasma cells. While several CD20-based antibodies have already demonstrated clinical benefit in various autoimmune conditions, CND261’s unique T-cell engager technology has the potential to significantly enhance efficacy. Having successfully completed a Phase 1 dose escalation study in oncology patients, Candid is now developing CND261 to address unmet needs in autoimmune diseases.
CND319 (CD19xCD20xCD3) Antibody
CND319 is a CD19xCD20xCD3 trispecific antibody designed to target the CD19 and CD20 antigens on a broad range of B-cell subtypes. CND319 is currently undergoing IND enabling studies.